Combination of Checkpoint Inhibitors and Intezyne’s Novel Cancer Resistance Pathway Inhibitor IT-139 Shows Enhanced Immune Efficacy

By WebmasterApril 10, 2018November 1st, 2024No Comments

Combination of Checkpoint Inhibitors and Intezyne’s Novel Cancer Resistance Pathway Inhibitor IT-139 Shows Enhanced Immune Efficacy

Previous PostHackensack Meridian Health Funds Key Innovation to Improve Health Care in New Jersey
Next PostDr. Ottavio Vitolo Joins Relmada Therapeutics as Senior Vice President, Head of R&D and Chief Medical Officer